Clinical Trial Update: A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) [Phase 3]

View source ↗

Summary

Phase 3 study of Nipocalimab in pregnancies at risk for severe hemolytic disease of the fetus and newborn (HDFN) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemolytic Disease of the Fetus and Newborn

Drugs mentioned

• Nipocalimab (nipocalimab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Hemolytic Disease of the Fetus and Newborn | Phase 3 | Status: RECRUITING